

Claim 40 (new):

The isolated polynucleotide of claim 39, wherein said polynucleotide has a C to T transition mutation at nucleotide 1591.

Claim 41 (new):

The isolated polynucleotide of claim 39, wherein said polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO. 3, or its full-length complement.

Claim 42 (new):

The isolated polynucleotide of claim 39, wherein said mutant c-Src polypeptide has a tyrosine residue at amino acid position 530.

Claim 43 (new):

The isolated polynucleotide of claim 39, wherein said mutant c-Src polypeptide comprises SEQ ID NO. 4.

Claim 44 (new):

A recombinant construct comprising a polynucleotide encoding a mutant c-Src polypeptide, wherein said polynucleotide encodes a stop codon at nucleotides 1591 to 1593.

Claim 45 (new):

The recombinant construct of claim 44, wherein said polynucleotide has a C to T transition mutation at nucleotide 1591.

Claim 46 (new):

The recombinant construct of claim 44, wherein said polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO. 3, or its full-length complement.

Claim 47 (new):

The recombinant construct of claim 44, wherein said mutant c-Src polypeptide has a tyrosine residue at amino acid position 530.

Claim 48 (new):

The recombinant construct of claim 44, wherein said mutant c-Src polypeptide comprises SEQ ID NO. 4.

Claim 49 (new):

The recombinant construct of claim 44, wherein said recombinant construct further comprises at least one regulatory element.

Claim 50 (new):

The recombinant construct of claim 49, wherein said recombinant construct is an expression vector.

Claim 51 (new):

CLY  
A transgenic cell having incorporated therein a recombinant construct, wherein said recombinant construct comprises:

- (a) a polynucleotide encoding a mutant c-Src polypeptide, wherein said polynucleotide encodes a stop codon at nucleotides 1591 to 1593; and
- (b) at least one regulatory element.

Claim 52 (new):

The transgenic cell of claim 51, wherein said polynucleotide has a C to T transition mutation at nucleotide 1591.

Claim 53 (new):

The transgenic cell of claim 51, wherein said polynucleotide comprises nucleotides 1 to 1593 of SEQ ID NO. 3, or its full-length complement.

Claim 54 (new):

The transgenic cell of claim 51, wherein said mutant c-Src polypeptide has a tyrosine residue at amino acid position 530.

Claim 55 (new):

The transgenic cell of claim 51, wherein said mutant c-Src polypeptide comprises SEQ ID NO. 4.

Claim 56 (new):

The transgenic cell of claim 51, wherein said recombinant construct is an expression vector.

Claim 57 (new):

An oligonucleotide capable of recognizing and distinguishing a mutant c-Src gene, wherein said mutant c-Src gene encodes a stop codon at nucleotides 1591 to 1593.

Claim 58 (new):

The oligonucleotide of claim 57, wherein said mutant c-Src gene has a C to T transition mutation at nucleotide 1591.

Claim 59 (new):

The oligonucleotide of claim 57, wherein said mutant c-Src gene comprises nucleotides 1 to 1593 of SEQ ID NO. 3.

Claim 60 (new):

The oligonucleotide of claim 57, wherein said mutant c-Src gene encodes a mutant c-Src polypeptide comprising SEQ ID NO. 4.

Claim 61 (new):

A diagnostic kit comprising an oligonucleotide capable of recognizing and distinguishing a mutant c-Src gene encoding a stop codon at nucleotides 1591 to 1593, and optionally a positive control comprising said mutant c-Src gene and a negative comprising a wild-type c-Src gene.

Claim 62 (new):

The diagnostic kit of claim 61, wherein said mutant c-Src gene has a C to T transition mutation at nucleotide 1591.

Claim 63 (new):

The diagnostic kit of claim 61, wherein said mutant c-Src gene comprises nucleotides 1 to 1593 of SEQ ID NO. 3.

Claim 64 (new):

CLY  
The diagnostic kit of claim 61, wherein said mutant c-Src gene encodes a mutant c-Src polypeptide comprising SEQ ID NO. 4.

Claim 65 (new):

The diagnostic kit of claim 61, wherein said wild-type c-Src gene comprises SEQ ID NO. 1.

Claim 66 (new):

A method for producing a mutant c-Src protein, said method comprising:

(a) culturing a transgenic cell under conditions suitable for expression of the mutant c-Src protein, wherein the transgenic cell has incorporated therein an expression vector comprising a polynucleotide encoding the mutant c-Src protein and at least one regulatory element, wherein said polynucleotide encodes a stop codon at nucleotides 1591 to 1593; and

(b) recovering the mutant c-Src protein from the cell or cell culture.

Claim 67 (new):

The method according to claim 66, wherein the mutant c-Src gene has a C to T transition mutation at nucleotide 1591.

Claim 68 (new):

The method according to claim 66, wherein the mutant c-Src gene comprises nucleotides 1 to 1593 of SEQ ID NO. 3.

Claim 69 (new):

The method according to claim 66, wherein the mutant c-Src protein comprises SEQ ID NO. 4.